Participants in this research study have been diagnosed with multiple myeloma. Multiple myeloma is a cancer of the plasma cells, found in bone marrow, the blood-producing tissue that fills in spaces within bone. This study is being done to see if the investigational drug (tabalumab) is safe and how well it work to help people with this particular cancer. Researchers also want to investigate how much tabalumab should be given. Does tabalumab with bortezomib and dexamethasone help people with myeloma. Also, to see if the combination of drugs is safe and what side effects are associated with them.
Karen Parrott, 319-353-6347
Participants in this study have been diagnosed with diffuse large B-cell lymphoma (DLBCL) that has either come back after therapy or that has become worse. The purpose of the study is to evaluate the effectiveness and side effects of treatment with 2 separate doses of the study drug (fostamatinib). The study will also evaluate the drug concentrations in the blood and how it is processed by the body. Study treatment will last as long as participant is receiving a benefit.
Mary Schall, 319-356-3516
Participants in this research study have metastatic renal cell carcinoma and have recently had surgery to remove the areas of cancer recurrence. The purpose of this study is to determine whether taking an oral drug known as pazopanib (Votrient®) will reduce the risk of the cancer recurring in the future. Pazopanib is approved by the U.S. Food and Drug Administration (FDA) for subjects who have metastatic renal cell carcinoma. However, it has not been tested in subjects who have had all visible areas of their cancer removed surgically, and is considered experimental (not approved by the FDA) in this situation. Investigators don't know if pazopanib will be helpful to subjects in this scenario. There is currently no standard of care for subjects in this situation but careful observation without treatment is considered reasonable. Approximately 14 people will take part in this study conducted by investigators at the University of Iowa. About 180 people may take part in this study nationwide.
Clarine Halvorsen, 319-356-3944
Participants in this research study have been diagnosed with angiosarcoma that is unable to be removed by surgery. The purpose of this research study is to find out what effects, good and/or bad, an experimental drug called AMG 386 has on the angiosarcoma. Approximately 5 people will take part in this study conducted by investigators at the University of Iowa. About 41 subjects will take part in this study nationwide. Study treatment will last as long as it is helping the cancer.
The purpose of this research study is to find out what effects, good and/or bad, there are to treating papillary kidney cancer with an investigational agent, ARQ 197, or a combination of ARQ 197 with erlotinib. ARQ 197 is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of papillary kidney cancer. Erlotinib is an investigational drug that has been approved by the FDA for the treatment of lung cancer but is not approved for the treatment of papillary kidney cancer. The combination of these two drugs (ARQ 197 and erlotinib) is also considered investigational. Approximately 6 people will take part in this study conducted by investigators at the University of Iowa. About 78 people will participate in this study nationwide.
Copyright © 2013 The University of Iowa. All Rights Reserved.